Literature DB >> 27318892

A preliminary examination of the validity and reliability of a new brief rating scale for symptom domains of psychosis: Brief Evaluation of Psychosis Symptom Domains (BE-PSD).

Hiroyoshi Takeuchi1, Gagan Fervaha2, Jimmy Lee3, Ofer Agid4, Gary Remington4.   

Abstract

BACKGROUND: Brief assessments have the potential to be widely adopted as outcome measures in research but also routine clinical practice. Existing brief rating scales that assess symptoms of schizophrenia or psychosis have a number of limitations including inability to capture five symptom domains of psychosis and a lack of clearly defined operational anchor points for scoring.
METHODS: We developed a new brief rating scale for five symptom domains of psychosis with clearly defined operational anchor points - the Brief Evaluation of Psychosis Symptom Domains (BE-PSD). To examine the psychometric properties of the BE-PSD, fifty patients with schizophrenia or schizoaffective disorder were included in this preliminary cross-sectional study. To test the convergent and discriminant validity of the BE-PSD, correlational analyses were employed using the consensus Positive and Negative Syndrome Scale (PANSS) five-factor model. To examine the inter-rater reliability of the BE-PSD, single measures intraclass correlation coefficients (ICCs) were calculated for 11 patients.
RESULTS: The BE-PSD domain scores demonstrated high convergent validity with the corresponding PANSS factor score (rs = 0.81-0.93) as well as good discriminant validity, as evidenced by lower correlations with the other PANSS factors (rs = 0.23-0.62). The BE-PSD also demonstrated excellent inter-rater reliability for each of the domain scores and the total scores (ICC(2,1) = 0.79-0.96).
CONCLUSIONS: The present preliminary study found the BE-PSD measure to be valid and reliable; however, further studies are needed to establish the psychometric properties of the BE-PSD because of the limitations such as the small sample size and lacking data on test-retest reliability or sensitivity to change.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Psychometrics; Psychosis; Reliability; Scale; Schizophrenia; Validity

Mesh:

Year:  2016        PMID: 27318892     DOI: 10.1016/j.jpsychires.2016.06.005

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  3 in total

1.  Reliability of the Glasgow Antipsychotic Side-effects Scale for Clozapine Japanese version (GASS-C-J).

Authors:  Kohei Kitagawa; Ryuhei So; Nobuyuki Nomura; Yuya Mizuno; Fuminari Misawa; Masafumi Kodama; Hiroyuki Uchida; Masaru Mimura; Hiroyoshi Takeuchi
Journal:  PLoS One       Date:  2020-06-18       Impact factor: 3.240

2.  Comprehensive assessment of exposure to clozapine in association with side effects among patients with treatment-resistant schizophrenia: a population pharmacokinetic study.

Authors:  Nobuyuki Nomura; Kohei Kitagawa; Ryuhei So; Fuminari Misawa; Masafumi Kodama; Hiroyoshi Takeuchi; Robert Bies; Thomas Straubinger; Christopher Banker; Yuya Mizuno; Masaru Mimura; Hiroyuki Uchida
Journal:  Ther Adv Psychopharmacol       Date:  2021-05-19

3.  Pharmacological treatment algorithms for the acute phase, agitation, and maintenance phase of first-episode schizophrenia: Japanese Society of Clinical Neuropsychopharmacology treatment algorithms.

Authors:  Hiroyoshi Takeuchi; Yoshiteru Takekita; Hikaru Hori; Kazuto Oya; Itaru Miura; Naoki Hashimoto; Norio Yasui-Furukori
Journal:  Hum Psychopharmacol       Date:  2021-07-09       Impact factor: 1.672

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.